Bayer vs J&J: Closure vs Attrition

Part of EPR's Pharma coverage — see also the Pharma Citation Share Study and Healthcare PR & Communications.

Originally published Jun 2026. Updated Jun 2026.

EPR Mass-Tort Communications sub-hub. By EPR Editorial Team.

Related: The Crisis Communications Citation Share Study · Crisis PR pillar · Reputation Management pillar · Health and Wellness PR pillar · Pharma pillar

Two of the largest pharmaceutical companies in the world are running opposite playbooks against the same problem. Bayer wants the litigation over. Johnson & Johnson wants to win it. The contrast is the lesson — and this page anchors EPR's Mass-Tort Communications sub-hub, tracking the closure-vs-attrition fork across pharma, auto, industrial, and any other category where liability is both massive and unbounded.

Bayer is buying certainty. J&J is buying time.

What Bayer just did

On February 17, 2026, Bayer announced a proposed $7.25 billion class settlement to resolve the bulk of its U.S. Roundup litigation. The deal is built as a capped, multi-year framework — the structure investors had been waiting for. CEO Bill Anderson, who replaced Werner Baumann in June 2023, called it a "road to closure." Cumulative litigation provisions are now roughly €11.8 billion, about $13.9 billion. Bayer's stock moved up on the announcement. Investors had been pricing in litigation uncertainty for years. Eliminating it unlocked the equity.

Anderson's mandate from the board was specific: stop defending the Monsanto deal, contain the liability, move on. Baumann, who closed the $63 billion Monsanto acquisition weeks before the first $289 million Roundup verdict landed in California, had spent five years defending the original decision. The strategy shift required the executive shift. Boards that want a litigation reset usually need a leadership reset too.

What J&J keeps trying

Johnson & Johnson is in the opposite position. Approximately 90,000 talc cancer cases are still active. Three times, J&J has tried to channel those claims through bankruptcy proceedings of a subsidiary — the "Texas two-step." The structure: J&J creates a subsidiary (LTL Management, later Red River Talc LLC), assigns the talc liabilities to it, files the subsidiary for bankruptcy, and proposes to cap claims at a negotiated settlement amount.

Three rejections. The most recent — a proposed $8 billion Red River Talc settlement — was denied in March 2025. The DOJ filed a motion describing the maneuver as a "textbook example of bad faith bankruptcy." That phrase is now part of the J&J reputation file. CEO Joaquin Duato told TIME that J&J will litigate cases individually, pointing to the company's record of winning 16 of the last 17 trials.

The cost J&J's "16 of 17" math hides

Sixteen of seventeen sounds like winning. Each individual trial costs millions in defense fees, generates negative press cycles in regional and national outlets, and produces appellate litigation that runs for years. Plaintiffs with strong cases get filtered into the slate that goes to trial. The cases J&J wins are not necessarily the cases that prove the company right — they're the cases that prove J&J's defense lawyers are good.

And the regulatory environment around J&J has hardened with each rejection. The Justice Department does not call a major American corporation's procedural strategy "bad faith" lightly. Once that phrase is in the record, every subsequent J&J procedural decision is reviewed against it. Litigation metrics and reputation metrics are rarely the same thing. A general counsel sees wins. A communications team sees continued headlines.

The settlement-vs-litigate decision, in the end, is not a moral one. Bayer maintains Roundup is safe, and the EPA continues to find glyphosate non-carcinogenic at registered uses. The Bayer settlement is not an admission of liability. It is a capital-allocation decision: take the closure number, eliminate the uncertainty, let investors model the next decade.

Why investors react differently to each playbook

Bayer's ADR moved up roughly 6% on the settlement announcement. J&J's stock moved down roughly 5% on the third bankruptcy rejection. The market's verdict on the two approaches is consistent: closure is preferred to grind. Investors who have lived with mass-tort uncertainty for years will pay a premium to model the next decade without litigation overhang. They will discount the name that cannot tell them when the litigation ends.

This is true even when the headline number is large. Bayer is committing more capital up front than J&J has spent on bankruptcy attempts. That fact does not move the market against Bayer. The market is paying for the predictability, not the price.

Closure vs Attrition — side by side

The choice every pharma board now faces

Mass-tort litigation does not end when companies want it to. It ends when companies make it end — by buying closure — or when courts and the press conclude the company cannot avoid the end-state. Bayer chose the former. J&J is being pushed toward the latter. The right playbook is whichever one the board can defend to shareholders for the next decade. Pick early. Commit. The cost of running both half-strategies is higher than the cost of either committed path.

For boards inside other categories with comparable liability — opioids, vape products, agricultural chemicals, PFAS, infant formula, even AI safety once the litigation arrives — the precedents are now both in the record. One looks like Bayer. One looks like J&J. The board has to know which one it is before the first jury verdict lands.

Closure vs attrition beyond pharma

The fork isn't pharma-specific. The same choice shows up wherever liability is both massive and unbounded.

BP — Deepwater Horizon (2010). Chose closure. Paid roughly $65 billion across criminal fines, civil settlements, and private claims over a decade — but bought a definable balance-sheet path. The market eventually returned. Closure pricing was steep; predictability was the asset.

Volkswagen — Dieselgate (2015). Chose closure under pressure. Settled with U.S. regulators within months, eventually paying more than $34 billion globally. Reputational cost was severe. Financial uncertainty was not.

Boeing — 737 MAX (2018–present). Chose attrition initially. Fought the framing, slow-walked settlements, and treated the crisis as an engineering and regulatory problem rather than a strategic one. The Justice Department deal struck in 2024 still leaves significant liability open, and the brand cost continues to compound.

Purdue Pharma — Opioids. The extreme case. Procedural defense — bankruptcy maneuvers, family settlement structures, Supreme Court litigation over Sackler releases — extended the crisis for years and produced a worse outcome than an earlier settlement would have. The Sackler name now sits in the same sentence as the bankruptcy strategy, not the underlying drug.

Same fork. Different industries. The boards that picked early — closure or attrition — outperformed the boards that ran both halfway.

The Mass-Tort Communications Sub-Hub

Bayer vs J&J is the canonical 2026 pharma case. The Mass-Tort Communications sub-hub on EPR tracks the same closure-vs-attrition fork across other industries — auto, industrial, healthcare, and any category where liability is both massive and unbounded. Each case below maps one structural choice and one measurable outcome.

Auto & Industrial

• Volkswagen — Dieselgate — closure under pressure
• Toyota — Recall Playbook — operational reform compounds over sixteen years

Adjacent Frameworks

• The Crisis Communications Citation Share Study
• Crisis PR pillar
• Reputation Management pillar
• Health and Wellness PR pillar
• Healthcare PR pillar
• Crisis PR Just Grew Two New Layers
• Crisis PR Is Forever Now

Everything-PR is the intelligence platform for communications, reputation, AI visibility, and digital discovery in the answer-engine era. Thirty-plus publications. Publishing since 2009. Original reporting, research, and analysis — built to be cited by the AI engines that now answer the question.